Premium
Comparison of treatments of infrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap
Author(s) -
Silvestri Maurizio,
Ricci Giano,
Rasperini Giulio,
Sartori Stefano,
Cattaneo Vitaliano
Publication year - 2000
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1034/j.1600-051x.2000.027008603.x
Subject(s) - enamel matrix derivative , dentistry , medicine , gingival recession , enamel paint , regeneration (biology) , treatment modality , orthodontics , surgery , biology , microbiology and biotechnology
Background, aims: The purpose of the present study was to compare the efficacy of 3 different surgical procedures in the treatment of infrabony defects: guided tissue regeneration (GTR) with non‐resorbable membranes, Widman modified flap (WMF) and enamel matrix derivative (EMD). Method: 30 patients with an infrabony component 4 mm were selected. 10 were treated with expanded polytetrafluorethylene (ePTFE (Gore – Tex W. L. Gore and Associates, Flagstaff, AZ, USA)) membranes, 10 with WMF and 10 with enamel matrix derivatives (Emdogain ® (Û Biora AB Malm, Sweden)). The efficacy of each treatment modality was investigated through regression analysis. Probing attachment level (PAL) gain, probing depth (PD) reduction and gingival recession (REC) variation were analyzed. Results: Both Emdogain ® (enamel matrix derivative) and ePTFE treatment show significant better results as compared to the WMF procedure in which there were no significant changes in PAL gain and PD reduction at baseline and 1 year after surgery. Conclusions: Results from our analysis suggest that there is no statistically significant difference in PAL gain between GTR and EMD. The clinical outcomes of this pilot study may be of little significance, considering the small number of patients, but it has provided an important base for a controlled clinical trial (with a larger number of patients) which is currently in progress.